Celsion founder steps down and takes away breast cancer treatment business for development
This article was originally published in Clinica
Celsion's founder and chief scientific officer, Dr Augustine Cheung, is to leave the company and work on further developing the breast cancer treatment he has bought from Celsion in a transaction worth up to $20m.
You may also be interested in...
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.